Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$269M |
| 2 |
Amazon
AMZN
|
+$242M |
| 3 |
Apple
AAPL
|
+$215M |
| 4 |
Amgen
AMGN
|
+$212M |
| 5 |
Citizens Financial Group
CFG
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$210M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$195M |
| 3 |
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
|
+$154M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$127M |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.58% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
YELL
2576
DELISTED
Yellow Corporation Common Stock
YELL
| $3.25M | ﹤0.01% |
574,417
-5,864
| -1% | -$34.1K |
|
|
BLUE
2577
DELISTED
bluebird bio
BLUE
| $3.25M | ﹤0.01% |
13,105
-21,765
| -62% | -$6.22M |
|
2578
Seres Therapeutics
MCRB
$45M
| $3.24M | ﹤0.01% |
23,294
+2,286
| +11% | +$447K |
|
|
GTHX
2579
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $3.22M | ﹤0.01% |
240,133
+329
| +0.1% | +$5.36K |
|
|
SFT
2580
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
| $3.22M | ﹤0.01% |
46,401
+4,693
| +11% | +$376K |
|
|
EPZM
2581
DELISTED
Epizyme, Inc
EPZM
| $3.22M | ﹤0.01% |
629,078
-7,320
| -1% | -$44.5K |
|
|
MMAT
2582
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $3.21M | ﹤0.01% |
5,552
+4,005
| +259% | +$1.75M |
|
2583
iQIYI
IQ
$1.31B
| $3.2M | ﹤0.01% |
398,022
+6,786
| +2% | +$70.4K |
|
2584
Independent Bank Corp
IBCP
$854M
| $3.19M | ﹤0.01% |
148,313
-25,602
| -15% | -$533K |
|
2585
Caribou Biosciences
CRBU
$160M
| $3.18M | ﹤0.01% |
+133,277
| New | +$3.26M |
|
2586
Invesco Short Term Treasury ETF
TBLL
$2.85B
| $3.17M | ﹤0.01% |
29,977
-3,455
| -10% | -$365K |
|
2587
Custom Truck One Source
CTOS
$2.33B
| $3.17M | ﹤0.01% |
339,287
+304,907
| +887% | +$2.57M |
|
2588
Noodles & Co
NDLS
$100M
| $3.15M | ﹤0.01% |
33,307
+4,766
| +17% | +$466K |
|
2589
Oscar Health
OSCR
$9.5B
| $3.13M | ﹤0.01% |
180,264
-1,210
| -0.7% | -$20.5K |
|
|
CYBR
2590
DELISTED
CyberArk
CYBR
| $3.12M | ﹤0.01% |
19,757
+1,221
| +7% | +$186K |
|
2591
UWM Holdings
UWMC
$2.61B
| $3.11M | ﹤0.01% |
447,041
+181,796
| +69% | +$1.35M |
|
2592
Alerus Financial
ALRS
$844M
| $3.11M | ﹤0.01% |
103,934
+3,800
| +4% | +$109K |
|
2593
Janus International
JBI
$686M
| $3.1M | ﹤0.01% |
+253,445
| New | +$3.46M |
|
|
NAPA
2594
DELISTED
The Duckhorn Portfolio, Inc.
NAPA
| $3.09M | ﹤0.01% |
134,797
-1,912
| -1% | -$41.7K |
|
2595
Omega Flex
OFLX
$291M
| $3.08M | ﹤0.01% |
21,582
+942
| +5% | +$143K |
|
|
KNTE
2596
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $3.07M | ﹤0.01% |
133,338
+43,288
| +48% | +$942K |
|
2597
Lindblad Expeditions
LIND
$2.26B
| $3.07M | ﹤0.01% |
210,330
-3,579
| -2% | -$50.3K |
|
2598
Alignment Healthcare
ALHC
$2.79B
| $3.06M | ﹤0.01% |
191,662
+1,336
| +0.7% | +$25.8K |
|
2599
908 Devices
MASS
$418M
| $3.05M | ﹤0.01% |
93,686
+45,836
| +96% | +$1.56M |
|
2600
Rigel Pharmaceuticals
RIGL
$762M
| $3.03M | ﹤0.01% |
83,387
+40,656
| +95% | +$1.6M |
|
Similar funds
Charles Schwab's Q3 2021 Portfolio in Review
As of Q3 2021, Charles Schwab held 3,610 positions worth $306B, up 1.6% from $301B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q3 2021 filing shows 202 new, 2,185 increased, 922 reduced and 109 closed positions. Its largest new stake was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M. The largest sale was Vanguard FTSE Emerging Markets ETF, an estimated $210M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q3 2021 buy was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M.
- Charles Schwab added most to Moderna in Q3 2021, an estimated $269M increase.
- Charles Schwab's biggest Q3 2021 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $210M.
- Charles Schwab fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $195M.
- Charles Schwab's ten largest holdings make up 17% of its $306B portfolio in Q3 2021.
- Charles Schwab opened 202 new positions and closed 109 in Q3 2021.
- Charles Schwab's portfolio value rose 1.6% quarter-over-quarter to $306B.
Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.